文献速递关节外科

静脉地塞米松对2型糖尿病患者全膝关节置换术后血糖控制的影响

Effects of Intravenous Dexamethasone on Glycemic Control in Patients With Type 2 Diabetes Mellitus After Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2021-08-08

这项回顾性研究纳入427例接受全膝关节置换术的糖尿病患者,比较使用与未使用静脉地塞米松(5mg,手术日及术后第1天各一次)两组。结果显示地塞米松对血糖的影响仅限注射当天,术前HbA1c高(而非地塞米松)增加术后血糖≥200 mg/dL和降糖药调整风险,术前HbA1c>7.05%与降糖药调整相关。

要点

  • 静脉地塞米松对血糖的升高作用仅限注射当天。
  • 术前高HbA1c而非地塞米松增加术后血糖≥200 mg/dL风险(OR 2.810)。
  • 术前HbA1c>7.05%与术后降糖药调整风险相关(OR 3.635,P<.001)。

核心结论

  • 静脉地塞米松对糖尿病患者全膝关节置换术后血糖有短暂升高作用,但术前HbA1c≥7.05%者术后可能需要调整降糖药物,与是否使用地塞米松无关。

研究设计与样本

  • 回顾性研究纳入427例接受全膝关节置换术的糖尿病患者,按是否使用静脉地塞米松分为两组。
  • 地塞米松组于手术日和术后第1天各给予静脉地塞米松5mg。

主要发现

  • 未用地塞米松组与地塞米松组手术日平均血糖分别为168.8 mg/dL和204.4 mg/dL,术后第1天分别为193.0 mg/dL和210.5 mg/dL。
  • 术前高HbA1c水平增加术后血糖≥200 mg/dL风险(OR 2.810)。
  • 术前高HbA1c水平增加降糖药调整风险(OR 3.635,P<.001)。
  • 术后并发症风险未见显著增加(OR 0.693,P=.552)。

关键数值与推荐

  • 术前HbA1c>7.05%与术后降糖药调整风险相关。
  • 静脉地塞米松对血糖控制的不良影响仅限于注射当天。

临床怎么用

  • 对术前HbA1c≥7.05%的糖尿病患者,全膝关节置换术后应关注降糖药调整需求,不论是否使用静脉地塞米松。
  • 使用静脉地塞米松者应重点监测注射当天的血糖水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to determine whether administrations of intravenous (IV) dexamethasone jeopardize blood glycemic control, increase rates of postoperative complications, and diabetic medication change after TKA. METHODS: This retrospective study included 427 patients with DM who underwent TKA. Patients were divided into two groups according to the use of IV dexamethasone (Dexa and No Dexa). For the Dexa, IV dexamethasone (5mg) was administered twice (surgery day, postoperative day 1). Blood glucose level until postoperative day 5, whether the mean blood glucose level was ≥200 mg/dL or not, the rate of a diabetic medication change, and postoperative complications (surgical site infection, delayed wound healing) were analyzed. RESULTS: The adverse effects of IV dexamethasone on glycemic control were limited to the day of injection. The mean blood glucose level was 168.8 mg/dL and 204.4 mg/dL on operation day and 193.0 mg/dL and 210.5 mg/dL on postoperative day 1 in the No Dexa and the Dexa, respectively. High preoperative glycated hemoglobin (HbA1c) levels, but not IV dexamethasone administration, increased the risk of postoperative blood glucose level ≥200 mg/dL (odds ratio [OR], 2.810) and diabetic medication change (OR, 3.635, P < .001). A preoperative HbA1c level of >7.05% was associated with the risk of diabetic medication change. There was increase of postoperative complications (OR, 0.693, P = .552). CONCLUSIONS: IV dexamethasone have transient effects on increasing the blood glucose level after TKA in patients with DM. However, patients with a preoperative HbA1c level of ≥7.05% may need to change their diabetic medication after TKA, regardless of IV dexamethasone administration.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Park HJ, Chang MJ, Kim TW, et al. Effects of Intravenous Dexamethasone on Glycemic Control in Patients With Type 2 Diabetes Mellitus After Total Knee Arthroplasty. J Arthroplasty. 2021. PMID: 34446328. doi:10.1016/j.arth.2021.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。